<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599844</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201500238</org_study_id>
    <nct_id>NCT02599844</nct_id>
  </id_info>
  <brief_title>Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults</brief_title>
  <acronym>IMPRESS-YA</acronym>
  <official_title>Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults - IMPRESS YA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Nephrology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is the most common cause of childhood death worldwide. Millions of children survive,
      but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly
      recognized as a significant factor associated with long-term mortality among different
      patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in
      the development of hypertension and cardiovascular disease. The investigators overall
      hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized,
      long-term consequences with regard to kidney function, endothelial function, blood pressure
      control, and overall health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a two-arm cross-sectional control-cohort outpatient evaluation. Subjects with
      sAKI and a random selection of non-sAKI subjects who agree to participate in another study of
      quality of life survey will be asked to participate in the outpatient study. Subjects will be
      asked to come in to the Clinical Research Center for 24-hour monitoring and participate in
      the outpatient study where urinary and serum studies to measure glomerular filtration rate,
      renal plasma flow followed by blood pressure monitoring, peripheral arterial and applanation
      tonometry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular Function Rate (GFR) filtration</measure>
    <time_frame>Day 2</time_frame>
    <description>Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal plasma flow (RPF) filtration</measure>
    <time_frame>Day 2</time_frame>
    <description>An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF) filtration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteinuria will be measured in the urine</measure>
    <time_frame>Day 2</time_frame>
    <description>Proteinuria may be a sign of renal (kidney) damage. Since serum proteins are readily reabsorbed from urine, the presence of excess protein indicates either an insufficiency of absorption or impaired filtration. People with diabetes may have damaged nephrons and develop proteinuria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystatin C will be measured in the blood</measure>
    <time_frame>Day 2</time_frame>
    <description>Cystatin C can be measured in a random sample of serum (the fluid in blood from which the red blood cells and clotting factors have been removed) using immunoassays such as nephelometry or particle-enhanced turbidimetry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microalbuminuria will be measured in the urine</measure>
    <time_frame>Day 2</time_frame>
    <description>The level of albumin protein produced by microalbuminuria can be detected by special albumin-specific urine dipsticks. A microalbumin urine test determines the presence of the albumin in urine. In a properly functioning body, albumin is not normally present in urine because it is retained in the bloodstream by the kidneys.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour ambulatory Blood Pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Arterial Tonometry</measure>
    <time_frame>24 hours</time_frame>
    <description>The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity</measure>
    <time_frame>24 hours</time_frame>
    <description>Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sepsis with Severe AKI</arm_group_label>
    <description>This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of &quot;injury&quot; or &quot;failure&quot;. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis without AKI</arm_group_label>
    <description>This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodohippurate</intervention_name>
    <description>An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)</description>
    <arm_group_label>Sepsis with Severe AKI</arm_group_label>
    <arm_group_label>Sepsis without AKI</arm_group_label>
    <other_name>RPF filtration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>24 hour ambulatory Blood Pressure</intervention_name>
    <description>Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.</description>
    <arm_group_label>Sepsis with Severe AKI</arm_group_label>
    <arm_group_label>Sepsis without AKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Arterial Tonometry</intervention_name>
    <description>The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.</description>
    <arm_group_label>Sepsis with Severe AKI</arm_group_label>
    <arm_group_label>Sepsis without AKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulse Wave Velocity</intervention_name>
    <description>Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.</description>
    <arm_group_label>Sepsis with Severe AKI</arm_group_label>
    <arm_group_label>Sepsis without AKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.</description>
    <arm_group_label>Sepsis with Severe AKI</arm_group_label>
    <arm_group_label>Sepsis without AKI</arm_group_label>
    <other_name>Magnevist Gadolinium (GD)</other_name>
    <other_name>Glomerular Function Rate (GFR) filtration</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intent to contact and enroll subjects with severe sepsis related AKI subjects without
        sepsis related AKI and a sample of age and sex-matched healthy controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all patients:

        â€¢ Age 18-24 at time of participation in the study

        For non-AKI sepsis patients:

          -  Hospitalization with a diagnosis of sepsis from 1998-2014

          -  Failure to meet pEDRIFLE criteria for AKI during incident sepsis admission

          -  Participation in cognitive survey study with completion of the PedsQL survey

        For sAKI patients:

          -  Hospitalization with a diagnosis of sepsis from 1998-2014

          -  Severe AKI as defined by the pEDRIFLE criteria during incident sepsis admission

          -  Participation in cognitive survey study with completion of the PedsQL survey

        Exclusion Criteria:

        For all patients:

          -  Known pre-existing CKD as defined by history of kidney transplant or long-term
             dialysis

          -  Age greater than 18 years at the time of incident sepsis admission

          -  AKI from primary kidney disease including acute glomerulonephritis and obstructive
             uropathy

          -  Pregnancy at the time of enrollment

          -  Known or suspected allergy to gadolinium based contrast

          -  Known or suspected allergy to iodine or shellfish will be excluded from RPF
             measurement with iodohippurate

          -  Heart failure or condition whereby the administration of 0.9% normal saline would be
             contraindicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Carmelle Elie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Carmelle Elie, MD</last_name>
    <phone>352-265-5911</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UF Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Carmelle Elie, MD</last_name>
      <phone>352-265-5911</phone>
      <email>elie@ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristy L Radeker, MSM</last_name>
      <phone>352-733-1462</phone>
      <email>kristylp@ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Carmelle Elie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

